Navigation Links
Value-Line Oxygen Double Flowmeters

ProductsValue-Line Oxygen Double Flowmeters
Company Western Medica
Item Value-Line Oxygen Double Flowmeters
Features 
  • Calibrated at 50 psi inlet
  • Optional power take-off units provide 50 psi additional outlet pressure
  • Double units for multi-patient use from one wall outlet
    • Description Value-Line oxygen flowmeters.
    Options:
  • For security chain, add suffix S to model number. Example: FMQ107S.
  • For Canadian Color-Code, add suffix FMQ104C.
  • For Double Flowmeters with Power Take-Off, add PT to model number. Example: FMQPT409.
    • Info Western Medica
    Customer Service: (800) 783-7890
    Web site: http://www.westernmedica.com/

    Related medicine products :

    1. Value-Line Oxygen Power Take Off Flowmeters
    2. Value-Line Oxygen Flowmeters
    3. LICOX Brain Tissue Oxygen Monitoring System
    4. PULSOX-2 Oxygen Saturation Monitor
    5. LOTUS™ Electronic Oxygen Conserver (with alarm)
    6. OXYMATIC® 401 Electronic Oxygen Conserver
    7. LOTUS™ Electronic Oxygen Conserver (without alarm)
    8. OXYMATIC® 401A Electronic Oxygen Conserver
    9. OXYMATIC® 411A Electronic Oxygen Conserver
    10. OXYMATIC® 411 Electronic Oxygen Conserver
    11. OXYMATIC® 411AF Electronic Oxygen Conserver
    Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 1U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 2U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 3U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 4U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 5West to Present at Two Upcoming Investor Conferences 56960 1West to Present at Two Upcoming Investor Conferences 56960 2Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 1Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 2